OBJECTIVE AND DESIGN: Among the options for treatment of diseases affecting the respiratory system, especially asthma, drug delivering systems for intranasal application represent an important therapeutic approach at the site of inflammation. The present study aimed to evaluate the therapeutic effect of biodegradable microparticles formed by poly lactic-co-glycolic acid (PLGA) containing encapsulated pomegranate extract on a murine model of asthma. MATERIAL: The extract was acquired from the leaves of P. granatum and characterized qualitatively by HPLC. A w/o/w emulsion solvent extraction-evaporation method was chosen to prepare the microparticles containing pomegranate encapsulated extract (MP). TREATMENT: OVA-sensitized BALB/c mice were used as asthma model and treated with dexamethasone and P. granatum extract in solution form or encapsulated into microparticles. RESULTS: MP were able to inhibit leukocytes' recruitment to bronchoalveolar fluid, especially, eosinophils, decreasing cytokines (IL-1β and IL-5) and protein levels in the lungs. CONCLUSIONS: This approach can be used as an alternative/supplementary therapy based on the biological effects of P. granatum for managing inflammatory processes, especially those with pulmonary complications.
OBJECTIVE AND DESIGN: Among the options for treatment of diseases affecting the respiratory system, especially asthma, drug delivering systems for intranasal application represent an important therapeutic approach at the site of inflammation. The present study aimed to evaluate the therapeutic effect of biodegradable microparticles formed by poly lactic-co-glycolic acid (PLGA) containing encapsulated pomegranate extract on a murine model of asthma. MATERIAL: The extract was acquired from the leaves of P. granatum and characterized qualitatively by HPLC. A w/o/w emulsion solvent extraction-evaporation method was chosen to prepare the microparticles containing pomegranate encapsulated extract (MP). TREATMENT: OVA-sensitized BALB/c mice were used as asthma model and treated with dexamethasone and P. granatum extract in solution form or encapsulated into microparticles. RESULTS: MP were able to inhibit leukocytes' recruitment to bronchoalveolar fluid, especially, eosinophils, decreasing cytokines (IL-1β and IL-5) and protein levels in the lungs. CONCLUSIONS: This approach can be used as an alternative/supplementary therapy based on the biological effects of P. granatum for managing inflammatory processes, especially those with pulmonary complications.
Authors: Roberto Nicolete; Cristina Rius; Laura Piqueras; Peter J Jose; Carlos A Sorgi; Edson G Soares; Maria J Sanz; Lúcia H Faccioli Journal: BMC Immunol Date: 2008-07-15 Impact factor: 3.615
Authors: L H Faccioli; V F Mokwa; C L Silva; G M Rocha; J I Araujo; M A Nahori; B B Vargaftig Journal: Mediators Inflamm Date: 1996 Impact factor: 4.711
Authors: Aruanã Joaquim Matheus Costa Rodrigues Pinheiro; Aleff Ricardo Santos Mendes; Milena Dara Farias de Jesus Neves; Carla Máximo Prado; Márcia Isabel Bittencourt-Mernak; Fernanda Paula Roncon Santana; João Henrique G Lago; Joicy Cortez de Sá; Claudia Quintino da Rocha; Eduardo Martins de Sousa; Valéria Costa Fontes; Marco Augusto Gregolin Grisoto; Angela Falcai; Lidio Gonçalves Lima-Neto Journal: Front Immunol Date: 2019-08-20 Impact factor: 7.561
Authors: Fernanda P R Santana; Rafael C da Silva; Simone Dos S Grecco; Aruanã J M C R Pinheiro; Luciana C Caperuto; Fernanda M Arantes-Costa; Samuel R Claudio; Kelly Yoshizaki; Mariângela Macchione; Daniel A Ribeiro; Iolanda F L C Tibério; Lídio G Lima-Neto; João H G Lago; Carla M Prado Journal: Mediators Inflamm Date: 2019-09-03 Impact factor: 4.711
Authors: Fernanda Paula R Santana; Nathalia M Pinheiro; Márcia Isabel B Mernak; Renato F Righetti; Mílton A Martins; João H G Lago; Fernanda D T Q Dos Santos Lopes; Iolanda F L C Tibério; Carla M Prado Journal: Mediators Inflamm Date: 2016-06-29 Impact factor: 4.711